<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>LENUS Collection:</title>
    <link>http://hdl.handle.net/10147/128324</link>
    <description />
    <pubDate>Sun, 19 May 2013 14:20:41 GMT</pubDate>
    <dc:date>2013-05-19T14:20:41Z</dc:date>
    <image>
      <title>LENUS Collection:</title>
      <url>http://www.lenus.ie:80/hse/retrieve/281884/SouthInfirmVictoria.jpg</url>
      <link>http://hdl.handle.net/10147/128324</link>
    </image>
    <item>
      <title>The prevalence and genotype of human papillomavirus on cervical samples from an Irish female population with external genital warts.</title>
      <link>http://hdl.handle.net/10147/275812</link>
      <description>Title: The prevalence and genotype of human papillomavirus on cervical samples from an Irish female population with external genital warts.
Authors: Cremin, Suzanne M; Menton, John F; Canier, Lydie; Horgan, Mary; Fanning, Liam J
Abstract: The aim of this study was to determine the cervical genotype profile of females who presented to an STI Clinic with external genital warts (EGW); and to determine the potential vaccine coverage prior to the uptake of the HPV vaccines. Sixty-one cervical scrapings were taken from females aged 18-35 y who had external genital warts or a history of external genital warts. The resulting 50 samples that were positive for HPV-DNA were subjected to genotype identification. Forty-six of these samples had detectable genotypes by LIPA analysis and most (78%, 36/46) had multiple low risk (LR) and high risk (HR) genotypes on the cervix. Twenty-five of these samples (54%) had more than 1 HR genotype. Of the 36 patients who had any HR genotypes, 18 (50%) were identified to have the most oncogenic HPV genotypes, namely 16 and 18. Three of these samples had both 16 and 18 on the cervix. The presence of multiple HR genotypes on the majority of cervical samples from a self-referred population of females with EGW is presented. This study is of importance since persistent HR-HPV is the necessary risk factor in the development of precancerous and cancerous lesions of the cervix. Gardisil, the quadrivalent HPV vaccine would have been useful in the prevention of 28% (13/46) of these infections.</description>
      <pubDate>Sun, 01 Jul 2012 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/10147/275812</guid>
      <dc:date>2012-07-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Initial results from the newborn hearing screening programme in Ireland.</title>
      <link>http://hdl.handle.net/10147/271523</link>
      <description>Title: Initial results from the newborn hearing screening programme in Ireland.
Authors: O'Connor, A; O'Sullivan, P G; Behan, L; Norman, G; Murphy, B
Abstract: INTRODUCTION: Hearing screening programmes aim to detect hearing loss in the neonate. The Health Service Executive (HSE) South was the first phase of a national roll-out of a neonatal hearing screening programme in Ireland, going live on 28 April 2011. RESULTS: Over 11,738 babies have been screened for permanent childhood hearing impairment (PCHI) during the first 12 months. The percentage of eligible babies offered hearing screening was 99.2 %. Only 0.2 % (n = 25) of those offered screening declined. 493 (4 %) were referred for immediate diagnostic audiological assessment. The average time between screen and diagnostic audiology appointment was 2 weeks. 15 (1.3/1,000) babies have been identified with a PCHI over the 12-month period. 946 (4 %) babies screened were admitted to the neonatal intensive care unit (NICU) for &gt;48 h. The prevalance of PCHI is 7.3/1,000 in the NICU population compared to 0.6/1000 in the well baby population. 214 (1.8 % of total babies screened) had a clear response in the screening programmes, but were deemed to be at risk of an acquired childhood hearing impairment. These babies will be reassessed with a diagnostic audiology appointment at 8-9 months of age. To date, there is one case of acquired hearing impairment through this targeted follow-up screen. Of the 15 cases of PCHI identified, 8 (53 %) of these had one or more risk factors for hearing loss and 7 (37 %) were admitted to the NICU for &gt;48 h. Four babies were referred for assessment at the National Cochlear Implant Centre.</description>
      <pubDate>Sat, 02 Mar 2013 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/10147/271523</guid>
      <dc:date>2013-03-02T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Double stenting in advanced colorectal cancer.</title>
      <link>http://hdl.handle.net/10147/270957</link>
      <description>Title: Double stenting in advanced colorectal cancer.
Authors: Khan, Ata; Baban, C K; Rajendran, S; Murphy, M; O'Hanlon, D M</description>
      <pubDate>Sat, 01 Jan 2011 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/10147/270957</guid>
      <dc:date>2011-01-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Second toe swelling: Nora's lesion or glomus tumour, case report and literature review.</title>
      <link>http://hdl.handle.net/10147/270495</link>
      <description>Title: Second toe swelling: Nora's lesion or glomus tumour, case report and literature review.
Authors: Mohammad, A; Kilcoyne, A; Blake, S; Phelan, M
Abstract: We report a rare case of bizarre parosteal osteochondromatous proliferation (BPOP, Nora's lesion) of the right second toe in a 60-year-old man who presented with painful, bluish and bulbous swelling of the right second toe without any break in the skin.</description>
      <pubDate>Sat, 01 Sep 2012 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/10147/270495</guid>
      <dc:date>2012-09-01T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

